4569 — Kyorin Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeMid CapSuper Stock

Annual income statement for Kyorin Pharmaceutical Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Tanshin
Standards:	JAS	JAS	JAS	JAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	102,904	105,534	113,270	119,532	130,087
Cost of Revenue
Gross Profit	51,628	49,441	50,168	51,408	59,536
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	96,056	100,851	107,741	114,013	117,862
Operating Profit	6,848	4,683	5,529	5,519	12,225
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	8,352	5,216	6,906	7,019	12,770
Provision for Income Taxes
Net Income After Taxes	6,130	3,932	4,724	5,323	9,086
Net Income Before Extraordinary Items
Net Income	6,130	3,932	4,724	5,323	9,086
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	6,130	3,932	4,723	5,322	9,086
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	88.8	73.2	77.7	100	164
Dividends per Share